FindTrial
Sign In

A study to analyse whether the type of glaucoma and combination of drugs affect the periocular changes.

Periorbital and ocular surface changes in patients on Prostaglandin Analogue eye drops.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/04/012949
Enrollment
60
Registered
2018-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL

Sponsors

Giridhar Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients on prostaglandin analogues for less than 6 months irrespective of glaucoma or combination of drugs used.

Exclusion criteria

Exclusion criteria: (a) Patients who has undergone any surgery other than cataract surgery (b) patients already detected with ocular surface diseases (c) patients having lid diseases like ptosis, thyroid related orbitopathy or lid tumours.

Design outcomes

Primary

MeasureTime frame
(a) Study orbital changes in patients on PGA by photographic documentation (b) Study ocular surface changes in patients on PGA by clinical examination pre and post 6 months.Timepoint: 12 months—

Secondary

MeasureTime frame
Comparative study will be done to assess the changes in various parameters and statistical analysis will be done.Timepoint: 12 months—

Countries

India

Contacts

Public ContactDr Marian Pauly

Giridhar Eye Instituter

drmarian@giridhareye.org8547505855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026